Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.
Hose D, Ray S, Rößler S, Thormann U, Schnettler R, de Veirman K, El Khassawna T, Heiss C, Hild A, Zahner D, Alagboso F, Henss A, Beck S, Emde-Rajaratnam M, Burhenne J, Bamberger J, Menu E, de Bruyne E, Gelinsky M, Kampschulte M, Rohnke M, Wenisch S, Vanderkerken K, Hanke T, Seckinger A, Alt V. Hose D, et al. J Hematol Oncol. 2024 Dec 18;17(1):128. doi: 10.1186/s13045-024-01636-4. J Hematol Oncol. 2024. PMID: 39695697 Free PMC article.
Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions.
Striegler C, Schumacher M, Effenberg C, Müller M, Seckinger A, Schnettler R, Voit B, Hose D, Gelinsky M, Appelhans D. Striegler C, et al. Among authors: hose d. Macromol Biosci. 2015 Sep;15(9):1283-95. doi: 10.1002/mabi.201500085. Epub 2015 May 28. Macromol Biosci. 2015. PMID: 26018141
Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.
De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E. De Veirman K, et al. Among authors: hose d. Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13. Cancer Immunol Res. 2017. PMID: 28903971
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A, Robert N, Heirman C, Cakana A, Hose D, Breckpot K, van Grunsven LA, De Veirman K, Menu E, Vanderkerken K, Moreaux J, De Bruyne E. De Smedt E, et al. Among authors: hose d. Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19. Cancer Res. 2018. PMID: 29259009
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A. Hose D, et al. J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5. J Hematol Oncol. 2019. PMID: 31242924 Free PMC article. Clinical Trial.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: hose d. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
330 results